To assess through quantitative and qualitative methods the influence of online continuing medical education (CME) in addressing clinician gaps on the calcitonin gene-related peptide (CGRP) pathway and its place in migraine treatment.

Advances on the CGRP pathway in migraine pathophysiology has led to an emerging class of agents with improved efficacy and safety in preventing migraines. Clinicians who manage migraineurs are challenged to apply these advances in practice.

A 1hr video-based CME activity launched live-online March 2019 and endured for 12 months. CME questions were administered pre-, immediate post-, and 8wk post-activity. Responses from CME, polling/live, and 8wk post-activity survey were analyzed to determine engagement, lessons learned, and continuing gaps. McNemar test compared matched pair responses (pre/post & pre/8wk) with Cohen’s d for effect size.

To date (full data available after March 2020), 70 of 341 learners completed questions from all 3 time points: 84% reported a positive impact on patient experience, and 83% reported a positive impact on clinical practice, with 104 qualitative write-in examples provided (eg, more confidence managing chronic migraines, improved ability to assess and differentiate CGRP monoclonal antibodies, to educate patients on CGRPs and address nonadherence, etc.). Pre-post comparisons of responses from all 5 CME test questions reflected statistically significant improvements on diagnostic criteria for chronic migraine, physiologic action of CGRP in migraine development, CGRP monoclonal antibody half-life, prophylactic selection and starting dose.